Genmedix

Genmedix was a pharmaceutical company specializing in the development and supply of generic injectable oncology medicines. Based in the United Kingdom, the company focused on providing high-quality, cost-effective alternatives to branded cancer treatments. Its portfolio included essential chemotherapy agents such as paclitaxel, carboplatin, and cisplatin. The company operated with a focus on the European market, ensuring supply chain reliability for critical hospital-administered drugs. In 2011, Genmedix was acquired by Teva Pharmaceutical Industries, a move that significantly expanded Teva's oncology footprint in Europe. Following the acquisition, the company's operations and product lines were integrated into Teva's global generics business.